In vivo silencing in specific cell types remains the main obstacle for therapeutic applications of siRNAs. Leuschner et al. now show that an optimized lipid nanoparticle delivers siRNA to inflammatory monocytes in mice and, when transporting CCR2 siRNA, has therapeutic effects in cardiovascular disease, cancer and transplant rejection.
- Florian Leuschner
- Partha Dutta
- Matthias Nahrendorf